Sinovac Holds 2010 Annual Meeting of Shareholders Beijing

Sinovac Holds 2010 Annual

Meeting of Shareholders

2010 Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of

vaccines in China, announced today that it held its 2010 Annual Meeting of

Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing

Time. The required quorum, a majority of

the common shares outstanding, was

voted in person or by proxy. The

meeting was held concurrently at No. 39 Shangdi Xi Road, Haidian District,

Beijing, PRC and at No. 6 Temple Street, St. John s, Antigua.

During the meeting, the

three proposals that required the affirmative vote of a majority of the shares

cast were approved as follows: all of the directors were re-elected; the

audited consolidated financial statements for financial year ended December 31,

2009 were approved and the selection of Ernst & Young as independent

auditors was confirmed. The three

proposals, which related to amending the Company s by-laws and required the

affirmative vote of a majority of common shares outstanding, were not approved.

Sinovac Biotech Ltd. is a China-based

biopharmaceutical company that focuses on the research, development,

manufacture and commercialization of vaccines that protect against human

infectious diseases. Sinovac s vaccine products include Healive (hepatitis A),

Bilive (combined hepatitis A and B), and Anflu (influenza). PanfluTM, Sinovac s pandemic influenza vaccine (H5N1), has already been approved

for government stockpiling. Sinovac is developing vaccines for enterovirus 71,

universal pandemic influenza, Japanese encephalitis, and human rabies. Its

wholly owned subsidiary, Tangshan Yian, is conducting field trials for

independently developed inactivated animal rabies vaccines. Its 30%-owned joint

venture, Sinovac Dalian, focuses on the research, development, manufacturing

and commercialization of vaccines, such as rabies, chickenpox, mumps and

rubella vaccines for human use.

For more information, please